Studies on effect of adefovir dipivoxil monotherapy or combination therapy with lamivudine for patients with lamivudine-resistant chronic hepatitis B
- VernacularTitle:阿德福韦酯单药或联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究
- Author:
Xianshan ZHOU
;
Mobin WAN
;
Ruiying ZHENG
- Publication Type:Journal Article
- Keywords:
hepatitis B,chronic;
lamivudine;
adeforvir dipivoxil;
drug resistance,viral;
mutation
- From:
Medical Journal of Chinese People's Liberation Army
1983;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of adefovir dipivoxil(ADV) monotherapy and ADV lamivudine(LAM) combined therapy for patients with LAM-resistant chronic hepatitis B.Methods 124 chronic hepatitis B patients with LAM-resistant mutations were enrolled in the present study.74 patients were treated with ADV combined with LAM therapy,and other 50 patients subjected to ADV monotherapy.There were no differences between the two groups in patients' baseline characteristics.Sequencing of the HBV polymerase gene was performed to determine LAM and ADV mutations occurred at baseline or during therapy.All patients were monitored with clinical examinations and routine laboratory tests during the therapy.Results The reduced logarithmic values of serum HBV DNA after 12-week and 24-week treatment were 1.99?0.64 and 2.61?0.80 in ADV group,obviously lower compared with those in ADV+LAM group(2.55?0.74 and 3.19?0.82,respectively,P
